London—May 2, 2016—Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announced that Chief Executive Officer Christian Hogg will present a corporate overview at two healthcare investor conferences in May.
Conference Details:
E
London: Wednesday, April 13, 2016: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) announces that the underwriters of its offering of American depositary shares (“ADSs”) on the Nasdaq Global Select Market (the “Offering”) have
London: Tuesday, April 12, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated the first-in-human (“FIH”) Phase I cli
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
London: Monday, March 21, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, has initiated SANET-p, a Phase III registration trial of s
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR
RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES,
CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE
TO DO SO WOULD CONS
Press Release
London: Wednesday, March 16, 2016: Hutchison China MediTech Limited ("Chi Med") (AIM: HCM) announces the pricing of its U.S. public offering of American depositary shares (“ADSs”) (the “Offering”), raising gross proceeds of app
London: Tuesday, March 15, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) today announces that its 2015 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Press Release
London: Friday, 4 March 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it intends to offer and sell, subject to market and other conditions, approximately $100 million of its ordinary shares in the f
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Record profit from operations at both Group and Commercial Platform levels
Excellent progress on all lead drug candidates – five out of five positive Phase Ib/II outcomes in 2015
Seven drug candidates – 19 active clinical trials – 3 Phase III
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTIT
Press Release
London: Wednesday, 9 December 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 joint venture with a subsidiary of Shanghai Pharma
The following includes the text of the Announcement, excluding the appendix. For the complete Announcement, please download the PDF.
---
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Press Release
London: Friday, 30 October 2015: Hutchison China MediTech Limited (“Chi‑Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, will present further scientific data on sulfa
London: Friday, 23 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, is set to receive a US$10 million milestone payment, in the fourt
Press Release
London: Friday, 16 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) announces that it has publicly filed today a registration statement on Form F-1 (the "Registration Statement") with the United States Securiti
London: Friday, 16 October 2015: Hutchison China MediTech Limited ("Chi-Med”) (AIM: HCM) today announces that, following the announcement that it had publicly filed a registration statement on Form F-1 ("Form F-1 Registration Statement") with the U
The following includes the text of the Announcement but excludes the appendix. For the complete release, please download the PDF.
---
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEM
Press Release
London: Tuesday, 13 October 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM) today announces that Hutchison MediPharma Limited (“HMP”), its drug R&D subsidiary, and AstraZeneca AB (publ) (“AstraZeneca”) ha
At the 2015 AIM Awards, Chi-Med was awarded the title of International Company of the Year.
The AIM Awards look at how companies and individuals harness AIM to power their growth and fulfil their strategy. The AIM Awards scrutinises recent joiners
For the complete release, please download the PDF.
---
Drug R&D Division - our Innovation Platform: enrolling 17 clinical trials (H1 2014: 10), with 24 targeted by year-end.
China Healthcare and Consumer Products Divisions - our Commercial
London: Thursday, 23 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that it has signed a subscription agreement (the "Agreement") and completed the exchange of 5,247,493 convertible preference shares held by Mitsui
London: Friday, 17 July 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL"), its prescription drug joint venture, has been granted an invention patent in China ("Inven
For the complete release, please download the PDF.
--
Break-out year for Drug R&D Division with 16 clinical studies on 7 drug candidates; 10 potential Breakthrough Therapy indications; as well as record China Healthcare Division revenues and
Press Release -
London: Thursday, 29 January 2015: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"),
Press Release -
London: Tuesday, 7 October 2014: Chi-Med today announces that it will host a briefing to update analysts and investors on Hutchison MediPharma Limited (“HMP”), its majority owned pharmaceutical R&D division, in London o
Press Release -
London: Wednesday, 1 October 2014: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces that Chi-Med, through its subsidiary Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company L